Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
02 mai 2023 16h45 HE
|
Senti Biosciences, Inc.
- Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology - - New preclinical data demonstrate...
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
17 avr. 2023 08h45 HE
|
Senti Biosciences, Inc.
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 – – Additional data presented on SENTI-301A...
Senti Bio to Participate in Upcoming Investor Conferences
14 avr. 2023 09h00 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
22 mars 2023 17h09 HE
|
Senti Biosciences, Inc.
- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - -...
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
14 mars 2023 16h35 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Biosciences Announces New Employment Inducement Grants
03 févr. 2023 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Present at the SVB Securities Global Biopharma Conference
01 févr. 2023 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
27 janv. 2023 08h00 HE
|
Senti Biosciences, Inc.
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other...
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
19 déc. 2022 07h55 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
11 déc. 2022 09h00 HE
|
Senti Biosciences, Inc.
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is...